ISSN 1674-3865  CN 21-1569/R
主管：国家卫生健康委员会
主办：中国医师协会
　　　辽宁省基础医学研究所
　　　辽宁中医药大学附属医院
中国中西医结合儿科学

中国中西医结合儿科学 ›› 2017, Vol. 9 ›› Issue (4): 312-314.doi: 10.3969/j.issn.1674-3865.2017.04.012

• 临床研究 • 上一篇    下一篇

孟鲁司特联合维生素C治疗儿童过敏性紫癜疗效观察

丁云峰，李志辉，段翠蓉，寻劢，吴天慧，张翼   

  1. 410007 长沙，湖南省儿童医院肾病风湿科
  • 出版日期:2017-08-25 发布日期:2017-12-08
  • 通讯作者: 李志辉，E-mail:lizh0731@al.gaa.com
  • 作者简介:丁云峰(1981-)，男，主治医师。研究方向：儿童肾病风湿病的诊治

Effect of montelukast combined with vitamin C in the treatment of children with allergic purpura

DING Yunfeng,LI Zhihui,DUAN Cuirong,XUN Mai,WU Tianhui   

  1. Department of Nephrotic Rheumatology,Hunan Children's Hospital,Changsha 410007,China
  • Online:2017-08-25 Published:2017-12-08

PDF (PC)

116

摘要：
目的
探讨孟鲁司特联合维生素C治疗儿童过敏性紫癜的临床疗效。
方法
2014年11月至2016年1月湖南省儿童医院肾病风湿科收治住院的过敏性紫癜患儿86例，随机分为对照组和观察组各43例。对照组采用孟鲁司特口服治疗，观察组在对照组治疗基础上应用维生素C特进行治疗，治疗7 d后对比两组患儿治疗后的临床效果、血浆细胞因子水平（白细胞介素6、白细胞介素8、肿瘤坏死因子α）变化以及不良反应。
结果
观察组总有效率为95.35%（41/43），显著高于对照组81.40%（35/43），差异有统计学意义（P<0.05）；治疗后观察组白细胞介素6、白细胞介素8、肿瘤坏死因子α血浆细胞因子水平显著低于对照组，差异有统计学意义（P<0.05）。观察组不良反应发生率为2.33%（1/43），显著低于对照组18.60%(8/43)，差异有统计学意义（P<0.05）。
结论
对过敏性紫癜患儿采用孟鲁司特联合维生素C治疗，效果显著，安全性好，不良反应低，值得临床推广使用。

关键词: 过敏性紫癜, 孟鲁司特, 维生素C, 联合治疗, 儿童

Abstract:
Objective
To investigate the clinical efficacy of montelukast combined with vitamin C in the treatment of allergic purpura in children.
Methods
From November 2014 to January 2010, 86 children with Henoch-Schonlein purpura were hospitalized and treated in the Department of Nephrotic Rheumatology, Hunan Children 's Hospital, and they were randomly divided into control group(43 cases) and observation group(43 cases). The control group was treated with montelukast orally taken. The observation group was treated with vitamin C in addition to monteleukast, and the treatment lasted for 7 days. The levels of plasma cytokine(interleukin 6, interleukin 8, tumor necrosis factor α) and adverse effects were compared between the two groups after treatment.
Results
The total effective rate was 95.35% (41/43) in the observation group, which was significantly higher than that in the control group (81.40%, 35/43), and the difference was statistically significant(P<0.05). After treatment, the level of interleukin 6,interleukin 8 and tumor necrosis factorα was significantly lower in the observation group than in the control group(P<0.05). The incidence of adverse events in the observation group was 2.33%(1/43),which was significantly lower than that of the control group(18.60%,8/43)(P<0.05).
Conclusion
The combination therapy of montelukast with vitamin C for children with Henoch-Schonlein purpura is effective and safe, with lower adverse reaction incidence. It is worthy of clinical application.

Key words: Allergic purpura, Montelukast, Vitamin C, Combination therapy, Children